NCT06656949 Sentinel Lymph Node Mapping With Different Injection Sites of ICG in Endometrium Cancer
| NCT ID | NCT06656949 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Qilu Hospital of Shandong University |
| Condition | Endometrial Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 42 participants |
| Start Date | 2024-10-30 |
| Primary Completion | 2025-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 42 participants in total. It began in 2024-10-30 with a primary completion date of 2025-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary goal of this prospective study is to define the efficacy of the sentinel lymph node biopsy (SLNB) procedure by comparing different method performed in patients with endometrial cancer. The aim of this study is to investigate whether the detection rate of sentinel lymph node (SLN) with two different injection sites may be increased compared to the standard use with single site (cervix) injection in endometrial cancer.
Eligibility Criteria
Inclusion Criteria: * • 1.Age \>18 and \<80 years old * 2\. The pathological diagnosis was epithelial ovarian cancer * 3.Survival time is expected to exceed 3 months * 4.Signed consent form Exclusion Criteria: * 1\. Patients with myocardial infarction or stroke, or unstable angina pectoris or decompensated heart function * 2.Patients with a history of exhaustion or deep vein thrombosis; * 3\. Liver insufficiency (transaminase \>2.5 times the upper limit of the standard); * 4\. Renal insufficiency (serum muscle liver \>2 times the standard upper limit); * 5\. Pregnancy and perinatal patients; * 6\. History of major organ transplantation and immune disease; * 7\. Psychiatric condition or language barriers * 8\. Alcohol or drug abuser (current or previous) * 9\. Unable or unwilling to sign informed consent or comply with study requirements; * 10\. Patients with other malignant tumors.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06656949 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 80 Years, studying Endometrial Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06656949 currently recruiting?
Yes, NCT06656949 is actively recruiting participants. Contact the research team at jin_peng@outlook.com for enrollment information.
Where is the NCT06656949 trial being conducted?
This trial is being conducted at Jinan, China.
Who is sponsoring the NCT06656949 clinical trial?
NCT06656949 is sponsored by Qilu Hospital of Shandong University. The trial plans to enroll 42 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.